Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Stefan R BornsteinDick de ZeeuwHiddo J Lambers HeerspinkFriedrich SchulzeLisa CroninArne WenzKatherine R TuttleSamy HadjadjEllen BurgessPublished in: Diabetes, obesity & metabolism (2024)
BI 690517 was generally well tolerated, reduced plasma aldosterone and may decrease albuminuria in participants with diabetes and albuminuric chronic kidney disease.
Keyphrases
- double blind
- placebo controlled
- chronic kidney disease
- phase iii
- phase ii
- clinical trial
- study protocol
- end stage renal disease
- type diabetes
- cardiovascular disease
- glycemic control
- phase ii study
- angiotensin ii
- randomized controlled trial
- peritoneal dialysis
- open label
- metabolic syndrome
- insulin resistance
- cross sectional
- radiation therapy
- weight loss